Bogos Krisztina, Kiss Zoltán, Gálffy Gabriella, Tamási Lilla, Ostoros Gyula, Müller Veronika, Urbán László, Bittner Nóra, Sárosi Veronika, Vastag Aladár, Polányi Zoltán, Nagy-Erdei Zsófia, Vokó Zoltán, Nagy Balázs, Horváth Krisztián, Rokszin György, Abonyi-Tóth Zsolt, Moldvay Judit
Department of Pulmonology, National Korányi Institute of Pulmonology, Budapest, Hungary.
MSD Pharma Hungary Ltd., Budapest, Hungary.
Front Oncol. 2019 Oct 23;9:1051. doi: 10.3389/fonc.2019.01051. eCollection 2019.
While Hungary is often reported to have the highest incidence and mortality rates of lung cancer, until 2018 no nationwide epidemiology study was conducted to confirm these trends. The objective of this study was to estimate the occurrence of lung cancer in Hungary based on a retrospective review of the National Health Insurance Fund (NHIF) database. Our retrospective, longitudinal study included patients aged ≥20 years who were diagnosed with lung cancer (ICD-10 C34) between 1 Jan 2011 and 31 Dec 2016. Age-standardized incidence and mortality rates were calculated using both the 1976 and 2013 European Standard Populations (ESP). Between 2011 and 2016, 6,996 - 7,158 new lung cancer cases were recorded in the NHIF database annually, and 6,045 - 6,465 all-cause deaths occurred per year. Age-adjusted incidence rates were 115.7-101.6/100,000 person-years among men (ESP 1976: 84.7-72.6), showing a mean annual change of - 2.26% ( = 0.008). Incidence rates among women increased from 48.3 to 50.3/100,000 person-years (ESP 1976: 36.9-38.0), corresponding to a mean annual change of 1.23% ( = 0.028). Age-standardized mortality rates varied between 103.8 and 97.2/100,000 person-years (ESP 1976: 72.8-69.7) in men and between 38.3 and 42.7/100,000 person-years (ESP 1976: 27.8-29.3) in women. Age-standardized incidence and mortality rates of lung cancer in Hungary were found to be high compared to Western-European countries, but lower than those reported by previous publications. The incidence of lung cancer decreased in men, while there was an increase in incidence and mortality among female lung cancer patients.
虽然匈牙利经常被报道肺癌发病率和死亡率最高，但直到2018年都没有进行全国性的流行病学研究来证实这些趋势。本研究的目的是通过回顾国家健康保险基金（NHIF）数据库来估计匈牙利肺癌的发病情况。我们的回顾性纵向研究纳入了年龄≥20岁、在2011年1月1日至2016年12月31日期间被诊断为肺癌（ICD-10 C34）的患者。使用1976年和2013年欧洲标准人口（ESP）计算年龄标准化发病率和死亡率。2011年至2016年期间，NHIF数据库每年记录6996 - 7158例新发肺癌病例，每年有6045 - 6465例全因死亡。男性年龄调整发病率为115.7 - 101.6/10万/人年（ESP 1976：84.7 - 72.6），平均年变化率为-2.26%（ = 0.008）。女性发病率从48.3/10万/人年增加到50.3/10万/人年（ESP 1976：36.9 - 38.0），平均年变化率为1.23%（ = 0.028）。男性年龄标准化死亡率在103.8 - 97.2/10万/人年之间（ESP 1976：72.8 - 69.7），女性在38.3 - 42.7/10万/人年之间（ESP 1976：27.8 - 29.3）。匈牙利肺癌的年龄标准化发病率和死亡率与西欧国家相比偏高，但低于以往出版物报道的水平。男性肺癌发病率下降，而女性肺癌患者的发病率和死亡率有所上升。
